Biedrba "Apvienba HIV.LV" (ik dienu pl. 9 - 21)
apvieniba@apvienibahiv.lv

 
   
106820

PENNVAX-GP acmredzot strd
Apskatt komentrus (0)


04.06.2019


Farmcijas kompnijas Inovio specilistiem izdevies izstrdt vakcnu, kas prbaudjumos, kuros piedaljs brvprtgie, uzrdja cergus rezulttus. Ir sperts vl viens nozmgs solis, lai palielintu imns atbildes ilgumu.
Izstrdt vakcna aktiviz organisma imno atbildi uz patognu un aizsarg no HIV seus mneus. Tas ir, cilvka  organisms spj pusgadu ne vien atpazt vrusu, bet ar sekmgi cnties ar to, izsargjoties no saslimanas ar HIV-infekciju. Iepriek visi minjumi radt vakcnu pret HIV beidzs ar neveiksmi organisma augsts imns tolerances d pret o patognu.
Turpmkie ptjumi un jaunas metodikas izstrdne, pamatojoties uz iegtajiem rezulttiem, var novest pie ilgtermia vakcnas radanas.
************************
Source: HIV Vaccine Candidate Generated Near 100% Immune Responses | https://www.precisionvaccinations.com/hvtn-098-pennvax-gp-hiv-vaccine-candidate-maintained-durable-and-robust-immune-responses-month-12 |
<... In a small, Phase 1 clinical study HVTN 098 PENNVAX-GP maintained durable and robust immune responses at month 12, which is a full 6 months after the last dose.
Previously PENNVAX-GP was reported by Inovio Pharmaceuticals, Inc. to elicit the highest overall levels of immune response rates ever demonstrated in a human study, by an HIV vaccine.
Inovio's HIV development focus is for both preventive and therapeutic purposes.
PENNVAX-GP consists of a combination of four HIV antigens designed to generate both antibody and T-cell responses and cover multiple global HIV strains. ...>




 
      Atpaka

atstj tuku: atstj tuku:
vrds:




Ievadiet drobas kodu:

Visual CAPTCHA